Evofem Biosciences Analyst Ratings
Evofem Biosciences Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
10/13/2022 | 414.4% | Stifel | $3 → $0.5 | Downgrades | Buy → Hold |
08/15/2022 | 4015.23% | HC Wainwright & Co. | $2 → $4 | Maintains | Buy |
07/15/2022 | 671.6% | Morgan Stanley | $2 → $0.75 | Maintains | Underweight |
06/02/2022 | 3500.82% | Laidlaw & Co. | → $3.5 | Initiates Coverage On | → Buy |
05/25/2022 | 1957.61% | Piper Sandler | $30 → $2 | Maintains | Overweight |
05/11/2022 | 1957.61% | Morgan Stanley | $8.55 → $2 | Maintains | Underweight |
05/10/2022 | 8696.3% | Morgan Stanley | $0.57 → $8.55 | Maintains | Underweight |
04/12/2022 | 486.42% | Morgan Stanley | $0.53 → $0.57 | Maintains | Underweight |
03/04/2022 | 445.27% | Morgan Stanley | $0.5 → $0.53 | Maintains | Underweight |
11/16/2021 | 1957.61% | HC Wainwright & Co. | $2.5 → $2 | Maintains | Buy |
10/21/2021 | 2472.02% | HC Wainwright & Co. | $4 → $2.5 | Maintains | Buy |
10/14/2021 | 723.05% | Morgan Stanley | → $0.8 | Downgrades | Equal-Weight → Underweight |
08/12/2021 | 928.81% | Morgan Stanley | $3 → $1 | Maintains | Equal-Weight |
06/07/2021 | 4015.23% | HC Wainwright & Co. | $7 → $4 | Maintains | Buy |
03/08/2021 | 7101.65% | HC Wainwright & Co. | $8 → $7 | Maintains | Buy |
10/02/2020 | 5044.03% | Stifel | → $5 | Initiates Coverage On | → Buy |
08/20/2020 | — | Morgan Stanley | Initiates Coverage On | → Equal-Weight | |
06/09/2020 | 9159.26% | HC Wainwright & Co. | $11 → $9 | Maintains | Buy |
06/08/2020 | 11216.87% | Piper Sandler | → $11 | Initiates Coverage On | → Overweight |
05/27/2020 | 25620.16% | Oppenheimer | $23 → $25 | Maintains | Outperform |
12/11/2019 | 11216.87% | HC Wainwright & Co. | $9 → $11 | Reiterates | → Buy |
10/16/2019 | 9159.26% | Cantor Fitzgerald | → $9 | Assumes | → Overweight |
09/26/2018 | 9159.26% | Cantor Fitzgerald | → $9 | Initiates Coverage On | → Overweight |
06/27/2018 | 8130.45% | RBC Capital | → $8 | Initiates Coverage On | → Outperform |
06/18/2018 | 9159.26% | Oppenheimer | → $9 | Initiates Coverage On | → Outperform |
03/19/2018 | 15332.1% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
2022 年 10 月 13 日 | 414.4% | Stifel | 3 美元 → 0.5 美元 | 降級 | 買入 → 持有 |
08/15/2022 | 4015.23% | HC Wainwright & Co. | 2 美元 → 4 美元 | 維護 | 買 |
07/15/2022 | 671.6% | 摩根士丹利 | 2 美元 → 0.75 美元 | 維護 | 體重不足 |
06/02/2022 | 3500.82% | Laidlaw & Co. | → 3.5 美元 | 啓動覆蓋範圍開啓 | → 購買 |
05/25/2022 | 1957.61% | 派珀·桑德勒 | 30 美元 → 2 美元 | 維護 | 超重 |
05/11/2022 | 1957.61% | 摩根士丹利 | 8.55 美元 → 2 美元 | 維護 | 體重不足 |
05/10/2022 | 8696.3% | 摩根士丹利 | 0.57 美元 → 8.55 美元 | 維護 | 體重不足 |
04/12/2022 | 486.42% | 摩根士丹利 | 0.53 美元 → 0.57 美元 | 維護 | 體重不足 |
03/04/2022 | 445.27% | 摩根士丹利 | 0.5 美元 → 0.53 美元 | 維護 | 體重不足 |
11/16/2021 | 1957.61% | HC Wainwright & Co. | 2.5 美元 → 2 美元 | 維護 | 買 |
2021 年 10 月 21 日 | 2472.02% | HC Wainwright & Co. | 4 美元 → 2.5 美元 | 維護 | 買 |
2021 年 10 月 14 日 | 723.05% | 摩根士丹利 | → 0.8 美元 | 降級 | 等重 → 減重 |
2021 年 12 月 8 日 | 928.81% | 摩根士丹利 | 3 美元 → 1 美元 | 維護 | 重量相等 |
06/07/2021 | 4015.23% | HC Wainwright & Co. | 7 美元 → 4 美元 | 維護 | 買 |
2021 年 8 月 3 日 | 7101.65% | HC Wainwright & Co. | 8 美元 → 7 美元 | 維護 | 買 |
10/02/2020 | 5044.03% | Stifel | → 5 美元 | 啓動覆蓋範圍開啓 | → 購買 |
2020 年 8 月 20 日 | — | 摩根士丹利 | 啓動覆蓋範圍開啓 | → 重量相等 | |
2020 年 9 月 6 日 | 9159.26% | HC Wainwright & Co. | 11 美元 → 9 美元 | 維護 | 買 |
06/08/2020 | 11216.87% | 派珀·桑德勒 | → 11 美元 | 啓動覆蓋範圍開啓 | → 超重 |
05/27/2020 | 25620.16% | 奧本海默 | 23 美元 → 25 美元 | 維護 | 跑贏大盤 |
2019 年 11 月 12 日 | 11216.87% | HC Wainwright & Co. | 9 美元 → 11 美元 | 重申 | → 購買 |
2019 年 10 月 16 日 | 9159.26% | 坎託·菲茨傑拉德 | → 9 美元 | 假設 | → 超重 |
09/26/2018 | 9159.26% | 坎託·菲茨傑拉德 | → 9 美元 | 啓動覆蓋範圍開啓 | → 超重 |
2018 年 6 月 27 日 | 8130.45% | 加拿大皇家銀行資本 | → 8 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
2018 年 6 月 18 日 | 9159.26% | 奧本海默 | → 9 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
2018 年 3 月 19 日 | 15332.1% | HC Wainwright & Co. | → 15 美元 | 啓動覆蓋範圍開啓 | → 購買 |
Evofem Biosciences Questions & Answers
Evofem 生物科學問題與解答
The latest price target for Evofem Biosciences (OTCQB: EVFM) was reported by Stifel on October 13, 2022. The analyst firm set a price target for $0.50 expecting EVFM to rise to within 12 months (a possible 414.40% upside). 12 analyst firms have reported ratings in the last year.
Stifel於2022年10月13日公佈了Evofem Biosciences(場外交易代碼:EVFM)的最新目標股價。該分析公司將目標股價定爲0.50美元,預計EVFM將在12個月內升至12個月內(可能上漲414.40%)。去年有12家分析公司公佈了評級。
The latest analyst rating for Evofem Biosciences (OTCQB: EVFM) was provided by Stifel, and Evofem Biosciences downgraded their hold rating.
Stifel提供了Evofem Biosciences(場外交易代碼:EVFM)的最新分析師評級,Evofem Biosciences下調了持有評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evofem Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evofem Biosciences was filed on October 13, 2022 so you should expect the next rating to be made available sometime around October 13, 2023.
分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與Evofem Biosciences的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級,因此每家公司每年應該獲得4次評級。Evofem Biosciences的最新評級是在2022年10月13日公佈的,因此您應該預計下一個評級將在2023年10月13日左右公佈。
While ratings are subjective and will change, the latest Evofem Biosciences (EVFM) rating was a downgraded with a price target of $3.00 to $0.50. The current price Evofem Biosciences (EVFM) is trading at is $0.10, which is out of the analyst's predicted range.
儘管評級是主觀的,並且會發生變化,但最新的Evofem Biosciences(EVFM)評級已下調,目標股價爲3.00美元,至0.50美元。Evofem Biosciences(EVFM)的當前交易價格爲0.10美元,超出了分析師的預測區間。